Actinium Pharmaceuticals Inc - חובות להיוון בספרים ATNM

Actinium Pharmaceuticals focuses on developing targeted radiopharmaceuticals for leukemia therapy, leveraging an academic approach and R&D investments. The primary challenges involve scaling production and the prolonged cycle of regulatory approvals. Geopolitical stability in the US minimizes external threats. The total debt-to-equity ratio illustrates leverage dynamics, where the metric level stands at 0.04.

Investors are assessing the potential of Actinium Pharmaceuticals (ATNM) through the resilience of its financial architecture. This metric compares total borrowings against total assets minus liabilities, determining the share of external financing within the capital structure. The current debt-to-equity coverage ratio is recorded at 0.04. Minimal reliance on loans is critical for a company developing costly radiopharmaceutical complexes under strict government regulation. This low indicator confirms the financial autonomy necessary to protect unique patents.